Literature DB >> 31625472

Navigating Alzheimer's Disease via Chronic Stress: The Role of Glucocorticoids.

Vivek Kumar Sharma1,2, Thakur Gurjeet Singh2.   

Abstract

Alzheimer's disease (AD) is a chronic intensifying incurable progressive disease leading to neurological deterioration manifested as impairment of memory and executive brain functioning affecting the physical ability like intellectual brilliance, common sense in patients. The recent therapeutic approach in Alzheimer's disease is only the symptomatic relief further emerging the need for therapeutic strategies to be targeted in managing the underlying silent killing progression of dreaded pathology. Therefore, the current research direction is focused on identifying the molecular mechanisms leading to the evolution of the understanding of the neuropathology of Alzheimer's disease. The resultant saturation in the area of current targets (amyloid β, τ Protein, oxidative stress etc.) has led the scientific community to rethink of the mechanistic neurodegenerative pathways and reprogram the current research directions. Although, the role of stress has been recognized for many years and contributing to the development of cognitive impairment, the area of stress has got the much-needed impetus recently and is being recognized as a modifiable menace for AD. Stress is an unavoidable human experience that can be resolved and normalized but chronic activation of stress pathways unsettle the physiological status. Chronic stress mediated activation of neuroendocrine stimulation is generally linked to a high risk of developing AD. Chronic stress-driven physiological dysregulation and hypercortisolemia intermingle at the neuronal level and leads to functional (hypometabolism, excitotoxicity, inflammation) and anatomical remodeling of the brain architecture (senile plaques, τ tangles, hippocampal atrophy, retraction of spines) ending with severe cognitive deterioration. The present review is an effort to collect the most pertinent evidence that support chronic stress as a realistic and modifiable therapeutic earmark for AD and to advocate glucocorticoid receptors as therapeutic interventions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer's disease; HPA axis; Stress; amyloid β; glucocorticoids; inflammation; neurodegeneration.

Mesh:

Substances:

Year:  2020        PMID: 31625472     DOI: 10.2174/1389450120666191017114735

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  5 in total

Review 1.  Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury.

Authors:  Heena Khan; Kunal Sharma; Amit Kumar; Amarjot Kaur; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2022-02-17       Impact factor: 4.575

Review 2.  Apoptotic Pathways and Alzheimer's Disease: Probing Therapeutic Potential.

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Shareen Singh; Nikhil Garg; Sonia Dhiman
Journal:  Neurochem Res       Date:  2021-08-12       Impact factor: 3.996

Review 3.  Dysbiosis and Alzheimer's Disease: A Role for Chronic Stress?

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Nikhil Garg; Sonia Dhiman; Saurabh Gupta; Md Habibur Rahman; Agnieszka Najda; Magdalena Walasek-Janusz; Mohamed Kamel; Ghadeer M Albadrani; Muhammad Furqan Akhtar; Ammara Saleem; Ahmed E Altyar; Mohamed M Abdel-Daim
Journal:  Biomolecules       Date:  2021-04-30

Review 4.  Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination.

Authors:  Rupinder Kaur; Shareen Singh; Thakur Gurjeet Singh; Pragati Sood; Jiki Robert
Journal:  Inflammopharmacology       Date:  2022-01-03       Impact factor: 5.093

Review 5.  Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases.

Authors:  Ruo-Lan Li; Ling-Yu Wang; Hu-Xinyue Duan; Qing Zhang; Xiaohui Guo; Chunjie Wu; Wei Peng
Journal:  Front Pharmacol       Date:  2022-09-22       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.